ABUSArbutus Biopharma
About Arbutus Biopharma
Arbutus Biopharma (NASDAQ:ABUS) is a biopharmaceutical company focused on discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a major cause of liver disease and liver cancer worldwide. With a keen eye on advancing a portfolio of drug candidates with diverse mechanisms of action, Arbutus aims to tackle this global health challenge from multiple fronts. Their strategy encompasses leveraging their expertise in RNA interference (RNAi) therapeutics, oral capsid inhibitors, and immune modulator drugs to achieve a functional cure for hepatitis B. Central to their mission is the commitment to transforming the treatment landscape of hepatitis B and significantly impacting the lives of millions of individuals afflicted by this chronic condition.
What is ABUS known for?
Snapshot
Public US
Ownership
2007
Year founded
91
Employees
Warminster, United States
Head office
1 of 4
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Products and/or services of Arbutus Biopharma
- Lipid Nanoparticle (LNP) Technology Development: Arbutus develops and engineers LNPs, which are microscopic spheres used to deliver therapeutic materials, like mRNA, into cells. Efficient LNP delivery is crucial for mRNA therapies to function properly.
- mRNA Delivery Solutions: Arbutus leverages its LNP technology to design and develop delivery systems specifically for mRNA-based therapeutics. This allows mRNA therapies to target specific tissues or organs within the body.
- GalXC™ Delivery Platform: GalXC™ is a proprietary LNP platform designed for efficient and targeted delivery of mRNA therapeutics. Arbutus might license this platform or its technology to other pharmaceutical companies developing mRNA therapies.
- Collaboration and Partnerships: Arbutus collaborates with pharmaceutical and biotechnology companies to develop and commercialize mRNA therapies using their LNP delivery systems.
- Preclinical and Clinical Development Programs: Arbutus might have its own pipeline of mRNA-based therapies in preclinical or clinical development stages for various diseases.
- Intellectual Property Portfolio: Arbutus has built an intellectual property portfolio around LNP technology and mRNA delivery, potentially including patents and licenses. They might generate revenue through licensing agreements with other companies.
Arbutus Biopharma executive team
- Ms. Lindsay Androski J.D., M.B.A.President, CEO & Chairman
- Mr. Tuan NguyenChief Financial Officer
- Mr. Andrew J. SungGeneral Counsel
- Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.Corporate Secretary